
Pyxis Oncology (PYXS) Stock Forecast & Price Target
Pyxis Oncology (PYXS) Analyst Ratings
Bulls say
Pyxis Oncology is supported by MICVO’s encouraging monotherapy profile in 2L+ R/M HNSCC, where 33 efficacy-evaluable patients produced a 36% cORR, 94% DCR, 6.2-month mPFS, and 12-month OS probability of 79%, while discontinuations fell to 14.3% after the dose cap, improving the tolerability case. The company also has multiple near-term catalysts, including updated 1L pembrolizumab-combination data in 4Q26, FDA dose-selection feedback in 1Q27, and updated OS data in 1H27, all of which could further de-risk the pivotal HEADLINER program planned for mid-2027. Financially, it reported a $20.0M net loss in 3Q26, ended with $57.0M in cash, and added about $110.0M from an October 1 offering, extending runway into 1H28 and strengthening execution flexibility.
Bears say
Pyxis Oncology is a small biotech with no revenues, leaving it heavily dependent on MICVO’s clinical success and external financing to fund ongoing R&D. The bearish view rests on the possibility of unacceptable toxicity, weaker-than-needed efficacy, an unfavorable therapeutic window, or regulatory setbacks such as clinical holds, any of which could halt development. Even with recent safety improvements, MICVO still must clear a pivotal trial in a highly competitive oncology market, and failure to do so could leave shares trading near cash, estimated at about $0.50 within 12 months.
This aggregate rating is based on analysts' research of Pyxis Oncology and is not a guaranteed prediction by Public.com or investment advice.
Pyxis Oncology (PYXS) Analyst Forecast & Price Prediction
Start investing in Pyxis Oncology (PYXS)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Pyxis Oncology (PYXS) Forecast
Pyxis Oncology (PYXS) Analyst Forecast & Price Prediction
Start investing in Pyxis Oncology (PYXS)
Order type
Buy in
Order amount
Est. shares
0 shares